Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KTX-951, a PROTAC designed for IRAK4 degradation (DC 50 =18 nM), exhibits an oral bioavailability (F%) of 22% in a rat model at a dosage of 10 mg/kg. Additionally, KTX-951 demonstrates promising anticancer potential [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | KTX-951, a PROTAC designed for IRAK4 degradation (DC 50 =18 nM), exhibits an oral bioavailability (F%) of 22% in a rat model at a dosage of 10 mg/kg. Additionally, KTX-951 demonstrates promising anticancer potential [1]. |
Molecular Weight | 850.95 |
Formula | C46H52F2N8O6 |
CAS No. | 2573298-36-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KTX-951 2573298-36-7 PROTAC PROTACs inhibitor inhibit